Lebrikizumab-Lbkz
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Comparison chart: Interleukin (IL) antagonists and oral JAK inhibitors for moderate to severe atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Drugs for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 23, 2026
Lebrikizumab After Multiple Prior Advanced Therapies in Moderate-To-Severe Atopic Dermatitis: A Real-World Case Series.
Journal: International journal of dermatology
Published: January 02, 2026
Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review.
Journal: The Annals of pharmacotherapy
Published: December 26, 2025
Nemolizumab (Nemluvio) for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
Comparison chart: Interleukin (IL) receptor antagonists for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: February 13, 2025
Lebrikizumab-lbkz.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: November 19, 2024
FDA approval of EBGLYSS™ (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and older.
Journal: Annals of medicine and surgery (2012)
Published: November 11, 2024
Lebrikizumab (Ebglyss) for atopic dermatitis.
Journal: The Medical letter on drugs and therapeutics
Published: November 07, 2024
Showing 1-12 of 12
Last Updated: 09/26/2026